Table 2.
Overall survival rates of patients initially treated with transarterial chemoembolization plus sorafenib (n=56) and transarterial chemoembolization alone (n=112)
| Overall survival rates | TACE plus Sorafenib, n (%) | TACE alone, n (%) | P |
|---|---|---|---|
| 1-year | 38 (67.9) | 13 (11.6) | <0.001 |
| 2-year | 21 (37.5) | 5 (4.5) | <0.001 |
| 3-year | 16 (28.6) | 2 (1.8) | <0.001 |
| 5-year | 6 (10.7) | 1 (0.9) | <0.001 |
TACE: Transarterial chemoembolization